MGP
NBIX icon

M&G plc’s Neurocrine Biosciences NBIX Stock Holding History

M&G plc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
88,261
-4,293
-5% -$637K 0.07% 164
2026
Q1 		$12.2M Buy
92,554
+955
+1% +$127K 0.06% 187
2025
Q4 		$13M Buy
91,599
+7,913
+9% +$1.15M 0.07% 190
2025
Q3 		$11.7M Buy
+83,686
New +$11.3M 0.06% 186
2024
Q2 		– Sell
-69,026
Closed -$9.53M – 422
2024
Q1 		$9.53M Buy
+69,026
New +$9.43M 0.04% 207

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

M&G plc's NBIX Position: Q2 2026 in Review

M&G plc reduced its Neurocrine Biosciences (NBIX) stake by 4.6% in Q2 2026, selling an estimated $637K and leaving 88,261 shares worth $14.9M. The position accounts for 0.07% of the portfolio, ranked #164.

M&G plc first reported a position in NBIX in Q1 2024 and has held it in 5 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • M&G plc held 88,261 shares of Neurocrine Biosciences worth $14.9M as of Q2 2026.
  • M&G plc sold 4,293 Neurocrine Biosciences shares in Q2 2026, an estimated $637K.
  • Neurocrine Biosciences made up 0.07% of M&G plc's portfolio in Q2 2026, its #164 holding.
  • M&G plc first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 5 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.